Could one of the knowledgeable ones on this forum (@ longreach?) please help me to understand a statement on page 6 of the recent investor presentation.
In the target market for WiSE - patients who have a right ventricle leadless pacemaker and who need CRT can only upgrade with WiSE.
Does this mean that patients who have a right ventricle leadless pacemaker for brachycardia or defibrillation, and then develop heart failure, need CRT by the left ventricle, but that left ventricle pacemakers with a lead cannot be used? What is currently being done for these patients? Does the right ventricle leadless pacemaker have to be taken out and a right ventricle pacemaker with a lead and a left ventricle pacemaker with a lead have to be inserted?
I apologize if this is a fact that could be found by scouring EBR releases .
I took only a small , not life-changing position. For anyone who has a much larger position, have you considered factors that would prevent FDA approval?
General Investor Information EBR Systems, page-118
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.5¢ |
Change
0.010(1.18%) |
Mkt cap ! $311.2M | |||
| Open | High | Low | Value | Volume |
| 85.0¢ | 85.8¢ | 84.0¢ | $48.01K | 56.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 29180 | 85.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 86.0¢ | 605 | 1 |
View Market Depth
| Last trade - 10.50am 07/10/2024 (20 minute delay) ? |
| EBR (ASX) Chart |